Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 9.12
(-0.44%)
CNY 9.12
(-0.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -200.8 Million CNY | -41.94% |
| 2022 | -141.47 Million CNY | -389.72% |
| 2021 | 48.83 Million CNY | -84.71% |
| 2020 | 319.3 Million CNY | 4.4% |
| 2019 | 305.83 Million CNY | 57.06% |
| 2018 | 194.72 Million CNY | 9.67% |
| 2017 | 177.55 Million CNY | 2.09% |
| 2016 | 173.9 Million CNY | 85.8% |
| 2015 | 93.6 Million CNY | 75.15% |
| 2014 | 53.44 Million CNY | 18.57% |
| 2013 | 45.07 Million CNY | 12.46% |
| 2012 | 40.07 Million CNY | 11.81% |
| 2011 | 35.84 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -39.61 Million CNY | -65.56% |
| 2024 Q1 | 1.46 Million CNY | 101.23% |
| 2024 Q2 | -23.92 Million CNY | -1729.45% |
| 2023 Q3 | -21.96 Million CNY | 25.62% |
| 2023 FY | -200.8 Million CNY | -41.94% |
| 2023 Q1 | -30.14 Million CNY | 83.91% |
| 2023 Q4 | -119.16 Million CNY | -442.58% |
| 2023 Q2 | -29.52 Million CNY | 2.05% |
| 2022 Q2 | 17.36 Million CNY | -37.88% |
| 2022 Q3 | 587.85 Thousand CNY | -96.61% |
| 2022 Q4 | -187.37 Million CNY | -31974.15% |
| 2022 FY | -141.47 Million CNY | -389.72% |
| 2022 Q1 | 27.95 Million CNY | 124.9% |
| 2021 Q1 | 74.3 Million CNY | 188.74% |
| 2021 Q2 | 78.06 Million CNY | 5.05% |
| 2021 Q4 | -112.24 Million CNY | -1389.57% |
| 2021 FY | 48.83 Million CNY | -84.71% |
| 2021 Q3 | 8.7 Million CNY | -88.85% |
| 2020 Q3 | 74.3 Million CNY | -45.14% |
| 2020 Q1 | 83.8 Million CNY | -6.68% |
| 2020 Q4 | 25.73 Million CNY | -65.37% |
| 2020 FY | 319.3 Million CNY | 4.4% |
| 2020 Q2 | 135.44 Million CNY | 61.62% |
| 2019 Q1 | 53.42 Million CNY | 142.54% |
| 2019 Q4 | 89.8 Million CNY | -11.82% |
| 2019 FY | 305.83 Million CNY | 57.06% |
| 2019 Q3 | 101.83 Million CNY | 67.57% |
| 2019 Q2 | 60.77 Million CNY | 13.75% |
| 2018 Q3 | 40.69 Million CNY | -42.04% |
| 2018 FY | 194.72 Million CNY | 9.67% |
| 2018 Q4 | 22.02 Million CNY | -45.87% |
| 2018 Q2 | 70.21 Million CNY | 13.64% |
| 2018 Q1 | 61.78 Million CNY | 62.17% |
| 2017 Q3 | 38.33 Million CNY | -23.87% |
| 2017 Q2 | 50.36 Million CNY | -0.76% |
| 2017 Q4 | 38.1 Million CNY | -0.62% |
| 2017 FY | 177.55 Million CNY | 2.09% |
| 2017 Q1 | 50.74 Million CNY | 20.23% |
| 2016 FY | 173.9 Million CNY | 85.8% |
| 2016 Q1 | 36.87 Million CNY | 26.08% |
| 2016 Q3 | 45.28 Million CNY | -8.6% |
| 2016 Q4 | 42.21 Million CNY | -6.78% |
| 2016 Q2 | 49.54 Million CNY | 34.35% |
| 2015 Q2 | 21.14 Million CNY | 7.77% |
| 2015 Q4 | 29.24 Million CNY | 23.98% |
| 2015 Q3 | 23.59 Million CNY | 11.57% |
| 2015 Q1 | 19.61 Million CNY | 98.39% |
| 2015 FY | 93.6 Million CNY | 75.15% |
| 2014 FY | 53.44 Million CNY | 18.57% |
| 2014 Q1 | 12.99 Million CNY | 0.0% |
| 2014 Q4 | 9.88 Million CNY | 0.0% |
| 2013 FY | 45.07 Million CNY | 12.46% |
| 2012 FY | 40.07 Million CNY | 11.81% |
| 2011 FY | 35.84 Million CNY | 0.0% |